EP3129021
Meðferð illkynja B-frumusjúkdóma með samsetningu af JAK og PI3K hemlum
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
7.4.2015EP published:
23.9.2020EP application number:
15717381.6
EP translation filed:
29.9.2020Grant published:
15.10.2020EPO information:
European Patent Register
Max expiry date:
6.4.2035Expiry date:
6.4.2026Next due date:
30.4.2026
Title:
TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITOR
Timeline
Today
7.4.2015EP application
23.9.2020EP Publication
29.9.2020Translation submitted
15.10.2020Registration published
6.4.2026Expires
Owner
Name:
Incyte Holdings CorporationAddress:
1801 Augustine Cut-Off, Wilmington, DE 19803, US
Inventor
Name:
SCHERLE, Peggy A.Address:
Swarthmore, PA 19081, US
Name:
LIU, XuesongAddress:
Hockessin, Delaware 19707, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
201461976815 PDate:
8.4.2014Country:
US
Classification
Categories:
A61K 31/397, A61K 31/437, A61K 31/502, A61K 31/519, A61P 35/00, A61P 35/02
Annual fees
Number
Paid
Expires
Payer
Number: 7
Paid: 18.3.2021
Expires: 6.4.2022
Payer: Sigurjónsson & Thor ehf.
Number: 8
Paid: 21.3.2022
Expires: 6.4.2023
Payer: Patice ehf.
Number: 9
Paid: 21.3.2023
Expires: 6.4.2024
Payer: Árnason Faktor ehf.
Number: 10
Paid: 7.3.2024
Expires: 6.4.2025
Payer: Árnason Faktor ehf.
Number: 11
Paid: 8.4.2025
Expires: 6.4.2026
Payer: Árnason Faktor ehf.